Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 1401Neoplasms 1128Prostatic Neoplasms 745Lung Neoplasms 621Colorectal Neoplasms 599Carcinoma, Non-Small-Cell Lung 570Carcinoma, Hepatocellular 414Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 356Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 310Head and Neck Neoplasms 290Neoplasm Metastasis 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 254Uterine Cervical Neoplasms 248Recurrence 248Melanoma 243Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 214Sarcoma 209Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 182

Interventions

Thyrotropin Alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER × DTC - Differentiated Thyroid Cancer × Clear all
NCT06405217 2024-05-08

Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment

Nanjing First Hospital, Nanjing Medical University

Phase NA Recruiting
30 enrolled
EndocrineHead & Neck

DTC - Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡